Bradley E. Patt, PhD ‐ Chairman & Chief Executive Officer
Dr. Patt has been chairman of Theracell since it’s inception in 2008 and has served as CEO of the Company since April 2012.
Brad has over 30 years experience as an entrepreneur and executive manager with a strong background in operations, finance, regulatory affairs and R&D of sophisticated leading-edge medical technology products. He has led several enterprises from start-up phase through rapid growth and has experience in executive team development, project management, human resource development, intellectual property as well as interfacing with investors, shareholders, advisors, customers, and commercial, industrial, academic, regulatory, and governmental partners.
Brad founded several high tech ventures since 1997. He previously was co-founder, CEO and Chairman of Gamma Medica, Inc. Brad built Gamma to market leadership position in preclinical CT, PET, SPECT imaging and is inventor and developer of Molecular Breast Imaging for detecting otherwise occult breast cancer in densebreasted women.
Brad is also cofounder and Director of EVO Worldwide, Inc. an advanced medical diagnostic imaging systems company; DxRay, Inc. an advanced digital xray detection company; Photon Imaging, Inc. a technology incubator; and Radiant Detector Technologies, Inc., sold to Seiko of Japan in 2005 now operating as Hitachi High Technology, USA, Inc. Brad also founded and is a Director of Thrive Outside the Box, a nonprofit organization that identifies and develops areas of talent in individuals on the autistic spectrum.
Brad is an internationally recognized authority in the field of medical imaging with over one hundred scientific papers and presentations, several book chapters, and 17 patents. He has been an invited speaker at several international conferences. He has held elected positions on the IEEE Nuclear Medicine Instrumentation Steering Committee (NMISC) and the IEEE Radiation Instrumentation Steering Committee (RISC), and was appointed to the Program Committee of the SPIE Medical applications of Penetrating Radiation, acting as Chairman of the Penetrating Radiation Work Group for 2003 and 2004. Dr. Patt is a consultant to the National Institutes of Health and the recipient of over $15 million dollars of grant awards as Principal Investigator from the National Institutes of Health, The United States Department of Energy and NASA.
Andrew J. Carter, PhD ‐ Chief Technology Officer
Andy has worked with TheraCell as Chief Technology Officer since March 2011 and has more than 30 years leadership experience in the medical device industry and is an expert in orthobiologics, orthopaedics, and biomaterials with more than 30 US patents and patent applications.
Andy is also Adjunct Associate Professor at the Prince of Wales Clinical School, UNSW, Sydney, Australia. Previous experience includes being the founder and President of Accent Biomedical, a provider of innovation services, and Chief Technology Officer at Anika Therapeutics, NASDAQ listed developer of hyaluronic acid based products for orthopedics, ophthalmics and aesthetic dermatology. Prior to this he was Vice President R&D and General Manager at Spine Wave Inc. a Connecticut based start up spine company. There he was responsible for development of injectable nucleus replacement and other motion preserving technologies. Andy spent over twenty years at Smith & Nephew, both in the US and UK. As Group Director of R&D at Smith & Nephew Endoscopy in Boston, USA he led 80+ engineers developing implants, RF and mechanical resection systems, fluid management systems for arthroscopy and endoscopy applications. He also led the company’s successful efforts to improve the effectiveness of the product development process. As Program Manager for Orthopedics and Endoscopy and Head of Materials Research at Smith & Nephew’s Group Research Center in York, UK he formulated and led long term research programs in orthopedics, spine and endoscopy, setting up joint ventures in tissue engineering and collaborative research programs with numerous universities.
Nelson Scarborough, PhD ‐ Chief Scientific Officer
Nelson has over 30 years of experience in the medical device space. He is a recognized expert in the orthobiologics field and has broad experience in sports medicine, wound healing, interventional spine and drug delivery. He is an inventor on over 45 issued US patents including key TheraCell technologies.
While Assistant Professor in the Department of Orthopaedics at the University of Florida, Dr. Scarborough became the Director of UF Tissue Bank where he gained extensive experience with all aspects of developing and managing tissue recovery, processing and distribution.
During his time at Osteotech Inc. Dr. Scarborough lead the R&D and Process Development programs and created several new technologies and products. He invented, characterized and published papers on the Athymic Rat Osteoinductive Assay which is now the basis for the current ASTM Standard. This assay provided a mechanism to guide development of demineralized bone matrix (DBM) products and lead to the first generation Demineralized Bone Fibers and products including Grafton Putty, Matrix, Flex, and Crunch. He also developed methods for viral inactivation of tissue and demonstrated effectiveness using in vitro and in vivo models.
While at Medtronic Spine and Biologics Dr. Scarborough was instrumental in developing the Progenix line of bone graft products. This included regulatory clearance, establishing manufacturing capabilities and qualifying custom raw materials. Nelson was also on the Infuse (rhBMP-2) technical advisory team. As Vice President of Research and Development for Covidien Sports Surgery Dr. Scarborough lead a team of 25 engineers developing products for meniscus, ACL and rotator cuff repair. This included mechanical devices and biologic solutions.
As Principal Scientist at LifeNet Health Dr. Scarborough lead the Research programs for ViviGen Cellular Bone Matrix and advanced bone healing technologies.
Nelson joined TheraCell, Inc. in 2012 as Chief Scientific Officer for the opportunity to develop new bone healing technologies in an entrepreneurial environment. This led to invention of the second generation of demineralized bone fibers and methods for processing and creating procedure specific products to facilitate intraoperative handling and bone healing potential.